| Segment / region | Type | Fiscal year | Currency | Revenue (millions) | Share of revenue |
|---|---|---|---|---|---|
| Health Benefits Segment | Product | 2025 | USD | 167,094.0 | 84.8% |
| Carelon Services Segment | Product | 2025 | USD | 71,716.0 | 36.4% |
| Segment Eliminations | Product | 2025 | USD | (41,689.0) | −21.2% |
| Health Benefits Segment | Product | 2024 | USD | 150,275.0 | 73.6% |
| Carelon Services Segment | Product | 2024 | USD | 53,922.0 | 26.4% |
| Health Benefits Segment | Product | 2023 | USD | 148,571.0 | 60.7% |
| Carelon Services Segment | Product | 2023 | USD | 95,964.0 | 39.2% |
| Other Segment | Product | 2023 | USD | 479.0 | 0.2% |
| Segment Eliminations | Product | 2023 | USD | (340.0) | −0.1% |
| Government Business Segment | Product | 2022 | USD | 96,810.0 | 68.1% |
| Commercial Specialty Business Segment | Product | 2022 | USD | 41,674.0 | 29.3% |
| IngenioRx Segment | Product | 2022 | USD | 14,974.0 | 10.5% |
| Other Segment | Product | 2022 | USD | 13,294.0 | 9.4% |
| Segment Eliminations | Product | 2022 | USD | (24,644.0) | −17.3% |
| Government Business Segment | Product | 2021 | USD | 82,919.0 | 66.7% |
| Commercial Specialty Business Segment | Product | 2021 | USD | 38,809.0 | 31.2% |
| IngenioRx Segment | Product | 2021 | USD | 12,776.0 | 10.3% |
| Other Segment | Product | 2021 | USD | 10,250.0 | 8.3% |
| Segment Eliminations | Product | 2021 | USD | (20,466.0) | −16.5% |
| Government Business Segment | Product | 2020 | USD | 71,572.0 | 59.2% |
| Commercial Specialty Business Segment | Product | 2020 | USD | 36,699.0 | 30.4% |
| IngenioRx Segment | Product | 2020 | USD | 10,384.0 | 8.6% |
| Other Segment | Product | 2020 | USD | 2,153.0 | 1.8% |
Product and geographic breakdowns describe the same revenue from different perspectives and should not be added together.
